Exelixis
EXEL Large CapHealthcare · Biotechnology
Aggiornato: May 2, 2026, 22:05 UTC
Metriche Chiave
Analisi della Valutazione
Informazioni sull'Azienda
Exelixis Stock at a Glance
Exelixis (EXEL) is currently trading at 37,26 € with a market capitalization of 9,5 Mrd. €. The trailing P/E ratio stands at 15.71x, with a forward P/E of 11.04x. The 52-week range spans from 28,80 € to 42,33 €; the current price is 12% below the yearly high. Year-over-year revenue growth stands at +5.6%. The net profit margin stands at 33.73%.
💰 Dividendo
Exelixis currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Raccomandazioni degli Analisti
17 analysts rate Exelixis (EXEL) on consensus: Comprare. The average price target is 40,54 €, implying +8.81% from the current price. Analyst price targets range from 29,86 € to 51,18 €.
Tesi di Investimento: Punti di Forza e Debolezze
- Profitable with 33.73% net margin
- High return on equity (35.53% ROE)
- High gross margin of 96.39% — indicates pricing power
- Analyst consensus: Buy
- Currently flagged as undervalued
- Solid balance sheet with low debt (D/E 9.3)
- Positive free cash flow
- –High short interest (15.1%)
Panoramica Tecnica
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profilo di Rischio
The data points to relatively defensive market behavior, elevated short interest (15.1%).
Dati di Trading
Azioni Correlate nello Stesso Settore
Where can I buy Exelixis?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
